13134-38-8

Usage

Uses

Since the provided materials do not mention any specific uses or applications for (PyrazinaMine, 3,6diMethyl, it is not possible to list its uses based on the given information. Further research and investigation would be required to determine its potential applications in various industries.

Upstream product

• 123-32-0 2,5-dimethyl-pyrazine 
• 83505-98-0 2-azido-3,6-dimethylpyrazine 
• 95-89-6 2,5-dimethyl-3-chloropyrazine 

Downstream Products

• 10212-66-5 N-(3,6-dimethyl-pyrazin-2-yl)-benzamide 
• 873377-13-0 N-acetyl-sulfanilic acid-(3,6-dimethyl-pyrazin-2-ylamide) 
• 5433-89-6 sulfanilic acid-(3,6-dimethyl-pyrazin-2-ylamide) 
• 1351515-90-6 1-amino-3,6-dimethylpyrazin-2(1H)-iminium 2,4,6-trimethylbenzenesulfonate 
• 1201689-16-8 (5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-ylmethyl)-triphenyl-phosphonium chloride 
• 1447715-68-5 [1-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]triphenyl phosphonium chloride 
• 1451735-27-5 5,8-dimethyl-2-[1-methyl-2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5a]pyrazine 
• 1451735-35-5 5,8-dimethyl-2-[(E)-1-methyl-2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-vinyl][1,2,4]triazolo[1,5a]pyrazine 

Relevant academic research and scientific papers

FUSED TRIAZOLE DERIVATIVES AS PHOSPHODIESTERASE 10A INHIBITORS

Compounds of the general formula (I), wherein one of X1 and X2 represents N, and the other one of X1 and X2 represents -C(CH3), A represents unsubstituted or substituted 5-, 6-or 10-membered aryl or h

NOVEL COMPOUNDS

The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

NOVEL COMPOUNDS

The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes

Studies on pyrazines; part 30: Synthesis of aminopyrazines from azidopyrazines

Azidopyrazines do not undergo reduction by reagents that are effective for the preparation of alkyl- or arylamines from the azides because the heterocyclic azides exist in the bicyclic form of tetrazolo[1,5-a]pyrazines. Nevertheless, the conversion into aminopyrazines was achieved by hydrogenolysis in the presence of ammonium hydroxide and palladium-on-carbon or particularly by reduction with tin(II) chloride in methanolic hydrochloric acid, in 34-87% yields. To elucidate the successful progress of the reaction, the equilibrium of azide-atetrazole was examined by 1H NMR spectroscopy in various solvents.